top of page
Contact Us
Contact Us

New Title. New Title. New Title. New Title. 

At CSI, we take a scientific approach to comparator sourcing based on our 25 years of experience in the clinical trial supply industry. Comparators are on the critical path of almost all clinical studies but are increasingly expensive and hard to find. We pride ourselves on finding the unfindable, sourcing comparator drugs that allow clinical trials to run on time and provide better patient outcomes.

Comparator Drug Sourcing

The clinical supply partner of choice

Pharmaceutical companies, biotechnology companies and Clinical Research Organisations (CROs) must have robust comparator sourcing strategies in place to ensure that comparator drugs are supplied to all clinical trial sites at a competitive price and without disruption. CSI has supplied medicines to over 1,000 clinical trials across lifecycle phases 1 to 4, supporting our partners with even the most complex and challenging requirements.
 
We understand that every clinical study is different and requires a customised approach. With the experience to take on even the most complex adaptive trials, we know how to reduce complexity and drive value, delivering sourcing strategies to improve the speed and agility of your study.

CSI delivers results with:

A comprehensive understanding of clinical trial requirements and protocols
Fully bespoke sourcing solutions, whether country-specific, global or hybrid
A global network of qualified suppliers, manufacturers and wholesalers
A wide range of suppliers to minimise risks and enable sourcing of specific batches
Full documentation, client support and supply chain transparency

CSI’s six drivers of effective comparator sourcing

Understanding the science behind a clinical trial informs CSI’s efficient supply strategies

Protocol interpretation

Protocol interpretation

Product access

Product access

Supply continuity

Supply continuity

Cost control

Cost control

Speed

Speed

Supporting documents

Supporting documents

Our most frequently supplied comparator medicines

Humira
adalimumab
Arthritis
Eylea
aflibercept
Ophthalmology
Tecentriq
atezolizumab
Oncology
Bavencio
avelumab
Oncology
Avastin
bevacizumab
Oncology
Yervoy
ipilimumab
Oncology
Abraxane
nab-paclitaxel
Oncology
Opdivo
nivolumab
Oncology
Ibrance
palbociclib
Oncology
Keytruda
pembrolizumab
Oncology
Lucentis
ranibizumab
Ophthalmology
Stivarga
regorafenib
Oncology
Mabthera
rituximab
Oncology
Jakavi
ruxolitinib
Oncology
Talzenna 
talazoparib
Oncology
Roactemra
tocilizumab
Arthritis

Branded Name

Scientific Name

Indication

Overcoming the challenges of comparator drug sourcing

The sourcing of comparator drugs and non-investigational medicinal products (NMPs) has become increasingly critical as most drugs are now tested against the standard of existing care. Despite market growth and development, it is becoming more difficult to guarantee the timely availability of comparator drugs due to many of the products being biologic medicines, which are difficult to produce and distribute.
 
Working with CSI will streamline your clinical trial supply chain and ensure high-quality comparator drugs are sourced in a timely and cost-effective manner. Our scientific expertise means we can advise on new investigative drugs and, with our global reach and emphasis on quality, you can always rely on us to deliver.

Oncology Products

CSI specialises in supplying oncology products to global clinical trials. We have successfully delivered oncology products to more than 700 studies, from generics to the most sophisticated cold chain biologics

Comedications

The standard of care for many indications, especially in oncology, is now a combination of drugs that together provide maximum efficacy. Comedications may be used to alleviate side effects or to improve the potency of the treatment. Comedications are common in cancer treatment because of the multitude of biological mechanisms at play in disease progression. Combination therapies play a crucial role in the comprehensive care of patients, from managing risks to creating synergies that give the gold-standard of treatment.

 

Critically, for clinical trials, the increasing prevalence of combination therapies being used as comparators means more complexity and greater risk from delays, drug shortages, disruptions and compromised supply chains. Securing multiple products on time, and in the right condition, is even harder when each requires a different supplier and logistics solution. 

 

CSI has the expertise and experience to help our partners to overcome these challenges. Our scientifically-minded team has the knowledge to advise on the optimal sourcing strategy for all comedications and combination therapies that might be required for any trial, factoring in origin of supply, price, logistics and shipment timing.

Rescue Studies

We apply our same expertise, global footprint and operational excellence in service of global studies that may need rescuing, whether this relates to issues of procurement, sourcing, resource, compliance, quality or timelines. With CSI’s decades of experience in the clinical trial supply industry and dedicated client relationship managers, we are here to help you get your study back on track. 

 

CSI has sourced rescue medications for a range of global studies, including the supply of salbutamol, Remicade (infliximab), Jakavi (ruxolitinib) and mycophenolate motefil.

bottom of page